Estimated impact of timely guidelines-based initiation of dual-combination anti-hypertensive therapy on long-term cardiovascular outcomes in a population of 1.4 million individuals.

26 August 2023 (09:06 - 09:24)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Professor Antonio Coca

Hospital Clinic, University of Barcelona, Barcelona (Spain)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on pharmacotherapy in hypertension

Professor A. Pathak (Luxembourg, LU)

Presentation thumbnail

Effect of initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy on ambulatory blood pressure indices

Doctor J. Nolde (Freiburg, DE)

Abstract Slides Video

Presentation thumbnail

Association of hydrochlorothiazide treatment compared to alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study

Doctor F. Goetzinger (Basel, CH)

Abstract Slides Video

Presentation thumbnail

Evening anti-hypertensive dosing, blood pressure and cardiovascular events in hypertensive: Updated meta-analysis of 41 trials in 65,271 patients

Doctor A. Sunjaya (Jakarta, ID)

Abstract Slides Video

Access the full session

Session thumbnail

Challenges in hypertension management

The Event

Event poster

ESC Congress 2023

26 August 2023 09:06 CET

You may be interested in

Congress Session

Challenges in hypertension management

Congress Presentation

Treatment patterns in a population of 1.4 million individuals qualifying for initiation of dual-combination blood pressure lowering therapy representing usual clinical practice.

Congress Session

Late-Breaking Clinical Trials: hypertension

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources